Business Context and Reporting Period
This Form 8-K is a current report filed by Aadi Bioscience, Inc. (not Whitehawk Therapeutics, Inc.) on March 2, 2023. The filing discloses significant changes in corporate leadership, specifically the resignation of the President and Chief Executive Officer and the appointment of an interim successor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive personnel changes and does not contain financial performance data.
Material Changes
- Resignation of CEO: Brendan Delaney resigned as President, Chief Executive Officer, and Director, effective March 14, 2023. The resignation was not due to any disagreement with management or the Board regarding operations, policies, or practices.
- Appointment of Interim CEO: Scott Giacobello, the Company's Chief Financial Officer, was appointed as Interim CEO and President, effective March 15, 2023. He will continue to serve as CFO.
- Executive Search: The Board has initiated a search for a permanent successor CEO. Mr. Giacobello's interim role will end upon the appointment of a successor.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or specific risk factors related to operations. However, it notes the following:
- Compensation: The compensation for Mr. Giacobello in his new interim role has not been finalized and will be disclosed in a future amendment to this report.
- Related Party Transaction: Mr. Giacobello purchased 20,000 shares of common stock for $250,000 in a private placement (PIPE Financing) on September 26, 2022, on the same terms as other investors.
- Leadership Transition: Neil Desai, Ph.D., the founder and former CEO, continues as Executive Chairman to assist with the transition.
Investor Verification Checklist
- Verify the timeline for the appointment of a permanent CEO to assess leadership stability.
- Monitor the upcoming amendment to this 8-K for details on the Interim CEO's compensation package.
- Review the Company's most recent 10-K or 10-Q filings for actual financial metrics, as this 8-K contains none.
- Confirm the status of the executive search process and any potential impact on ongoing clinical trials or business operations.